Figure 7
From: BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer
Silencing of BCL2A1 mRNA increases CHCP treatment potency. Bar graphs showing the (A) effects of BCL2A1 esiRNA silencing on cell viability and (B) the fold change of BCL2A1 mRNA and (C) protein expression in MDA-MB-231 cell line in combination with CAP treatment. At 24 h. after transfection with BCL2A1 esiRNA (13 pmol), as mentioned in the methods section survival of treatments was determined by MTT assay and BCL2A1 fold change by qRTPCR and western blots. (D) and (E) show a representative blot for BCLA1 and total protein respectively. The error bars represent means ± SEM. (n = 3). (****p < 0.0001, *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t-test) versus control.
